PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Patient Spotlight A Mayo Pathologist’s Journey through Paraneoplastic Syndrome and a Double Lung Transplant: Dr. Brad Karon

Microlearning Neurodegenerative Diseases: Diagnostic Advancements

Answers From the Lab Advancing Neuropathy Diagnosis With Laboratory Testing and Algorithms: Div Dubey, M.B.B.S

Answers From the Lab Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders

Eye on Innovation Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS

Patient Spotlight Innovative SORD test provides clarity for two young patients

NEUROLOGY TEST SPECIALTIES

Autoimmune disorders

Biopharma testing

Demyelinating disease

Dementia

Epilepsy

Movement disorders

Neurogenetics

Neuromuscular disorders

Pediatrics

Peripheral neuropathy

“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”
John Mills, Ph.D., co-director, Neuroimmunology Laboratory

OUR DIFFERENCE

Clinically driven neurology test menu
Consolidate more of your sendout testing to one trusted lab.

Solving the most complex neurologic cases
We continually innovate to develop new testing approaches that enable answers to the rarest and most complex neurological conditions.

Backed by the world’s leading experts
Our laboratories are led by clinical neurologists who have extensive experience using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.

News and updates

The latest

MOG-IgG as a marker of acute disseminated encephalomyelitis

Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.

Learn more

MOG-IgG as a marker of acute disseminated encephalomyelitis

Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.

Autoimmune Neurology: Phenotype-Based Testing

Register now – May 19, 2026 This webinar will discuss how autoimmune neurology testing has changed with expanding antibody discovery and why a patient-first, phenotype-specific approach improves test selection and interpretation.

Multiple Sclerosis: Diagnostic Criteria Update and Kappa Free Light Chain Testing

Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.

Pediatric Autoimmune Neurologic Disorders

In this presentation, Eoin Flanagan, M.B., B.Ch., a leading specialist in neuroimmunology at Mayo Clinic, provides a clear and clinically focused overview of autoimmune conditions that affect the developing nervous system.

Breakthrough Test Enhances Peripheral Neuropathy Care and Research

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.

Precision epilepsy testing

Learn more about how Precision Epilepsy testing at Mayo Clinic Laboratories enables a holistic diagnostic care experience that supports better outcomes for patients with epilepsy.

Alzheimer’s Disease Blood Biomarkers

This presentation offers a clear introduction to emerging blood based biomarkers for Alzheimer’s disease.

AQP4-IgG FACS Assay Update

Mayo Clinic Laboratories invites you to explore our latest microlearning on neuromyelitis optica spectrum disorder (NMOSD). In this concise educational module, Sean Pittock, M.D., explains the critical role of AQP4-IgG testing in the early diagnosis and treatment of NMOSD.

Rational Approaches to Testing in the MCI/Dementia Setting

In this video, Dr. Vijay Ramanan shares perspectives on rational approaches to testing in the cognitive neurology, mild cognitive impairment, and dementia settings.

Autoimmune Neurology: Phenotype-Based Testing

November 3, 2025 - In this video, Dr. Andrew McKeon describes how the field of autoimmune neurology testing has changed with the explosion of antibody discovery and discusses the importance of a patient-first, phenotype-based approach.

CNS Demyelinating Diseases and Pediatric Profiles

September 29, 2025 - This session provides an in depth overview of evolving diagnostic approaches in neuroimmunology.

Advancing precision diagnostics for neurodegenerative disorders

SAAmplify™-αSYN testing offers unprecedented accuracy in diagnosing Parkinson’s and Lewy body dementia.